Form 4 · Filed Jun 16, 2026, 10:36 AM UTC
ADIL/ADIAL PHARMACEUTICALS, INC.
Davidson Matt — Chief Development Officer
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
6 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 12, 2026 | A | other | 232,417 | $0 | — | 297,491 |
| Jun 12, 2026 | A | other | 232,417 | — | — | 232,417 |
| Jun 11, 2026 | A | other | 61,647 | — | — | 61,647 |
| Jun 11, 2026 | A | other | 3,427 | — | — | 3,427 |
| Jun 11, 2026 | A | other | 1,822 | — | — | 1,822 |
| Jun 11, 2026 | A | other | 101 | — | — | 1,923 |
Source: SEC EDGAR raw filing ↗ · Accession 0001213900-26-069037